Rhelion Life Sciences completes ibogaine extraction

Rhelion Life Sciences, through its subsidiary Filament Health, has successfully completed the extraction of IBEX011 ibogaine, according to a report by Kalkine CA. This development marks a significant step in the company's ongoing research and development efforts focused on ibogaine, a psychoactive compound being studied for its potential therapeutic effects on conditions such as opioid use disorder and PTSD.

Filament Health's Extraction Process

Filament Health, a subsidiary of Rhelion Life Sciences, has finalized the extraction process for IBEX011, a specific formulation of ibogaine. This achievement is part of the company's broader initiative to explore the therapeutic potential of ibogaine, which is derived from the root bark of the African shrub Tabernanthe iboga.

Launch of Stability Testing

Following the successful extraction, Filament Health has commenced stability testing of the IBEX011 ibogaine formulation. Stability testing is a critical phase in pharmaceutical development, ensuring that the compound maintains its efficacy and safety over time. This step is essential for advancing towards potential clinical trials and eventual therapeutic use.

Why It Matters

The completion of the IBEX011 extraction and the initiation of stability testing are pivotal in advancing ibogaine research. Ibogaine is being investigated for its potential to treat a range of conditions, including opioid addiction and PTSD, which are significant public health challenges. The progress made by Rhelion Life Sciences and Filament Health could contribute to the development of new treatment options for these conditions.

This development underscores the growing interest in psychedelic compounds for therapeutic use and highlights the ongoing efforts to establish ibogaine as a viable treatment option.